hat
Konsa byen lwen, Crispr ki tou nèf pou somatiques sèlil toute modification Terapi pou rantre nan tras klinik. Men, Jennifer Doudna, espere pou yo kòmanse nan kèk ane. "Si l' byen, Mwen panse ke nou te kapab wè thérapeutique apwouve nan yon dekad,"li te di. Nan labo, w ap itilize tou de moun sèlil somatiques reyinifikasyon ak modèl animal, chèchè sont expérimenter ak maladi, kouto digo sèlil anémie ap trete yon malad, grave combinée Imino (SCID), sou non-au, haemophilia, isk k ap mouri nèt ak Fibróz sistik. (Approche pou pwoblèm moun ki pa marye jèn sa yo te baze sou yo pandan l ajoute yon nouvo moso DNA pou m korije jèn défectueux a.)
eng
Thus far, Crispr is too new for any somatic cell editing therapy to have entered clinical trials. But Jennifer Doudna expects them to begin within a few years. “If they go well, I think we could see approved therapeutics within a decade,” she says. In the lab meanwhile, using both human somatic cell cultures and animal models, researchers are experimenting with treating diseases including sickle cell anaemia, severe combined immunodeficiency (SCID), beta-thalassemia, haemophilia, muscular dystrophy and cystic fibrosis. (The approach for these single gene disorders is based on adding a new piece of DNA to correct the faulty gene.)